Samer Al Hadidi, Associate Professor at UAMS – University of Arkansas for Medical Sciences, shared a post on X:
“Check our recent work: Bispecific antibody therapy in CNS myeloma: Early evidence from a multicentre cohort
– 100% CNS response (n=6 evaluable)
– 2 pts responded before CNS-directed therapy
– No grade ≥3 CRS or ICANS.”
Title: Bispecific antibody therapy in CNS myeloma: Early evidence from a multicentre cohort
Authors: Alexandra Noveihed, Samer Al Hadidi, Meera Mohan, Mansi R. Shah
More posts featuring Samer Al Hadidi on OncoDaily.
